Shanghai Fosun Inks $531M Deal with Swiss Giant Sellas
HONG KONG – Looking to expand its global footprint, China’s largest biotech, Shanghai Fosun Pharmaceutical Group, has inked a potential $531 million deal with Switzerland’s Sellas Clinicals Holding Ag for two drug candidates. The deal not only gives Fosun cash to continue its focus on drug development, but also allows Sellas to diversify its product offerings and sources of new drugs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST